Defining breast cancer intrinsic subtypes by quantitative receptor expression

Oncologist

Volumn 20, Issue 5, 2015, Pages 474-482

  Cheang, Maggie C U ^a,c   Martin, Miguel ^d   Nielsen, Torsten O ^e   Prat, Aleix ^f   Voduc, David ^g   Rodriguez Lescure, Alvaro ^h   Ruiz, Amparo ⁱ   Chia, Stephen ^g   Shepherd, Lois ^j   Ruiz Borrego, Manuel ^k   Calvo, Lourdes ^l   Alba, Emilio ^m   Carrasco, Eva ⁿ   Caballero, Rosalia ⁿ   Tu, Dongsheng ^j   Pritchard, Kathleen I ^o   Levine, Mark N ^p   Bramwell, Vivien H ^q   Parker, Joel ^a,b   Bernard, Philip S ^r   Ellis, Matthew J ^s   Perou, Charles M ^a,b   Di Leo, Angelo ^t   Carey, Lisa A ^a   more..

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

ⁱ INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^j Institut national du cancer du Canada   (Canada)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l HOSPITAL JUAN CANALEJO   (Spain)

^m HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁿ P de la Castellana 181   (Spain)

^o UNIVERSITY OF TORONTO   (Canada)

^p MCMASTER UNIVERSITY   (Canada)

^q UNIVERSITY OF CALGARY   (Canada)

^r UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^s WASHINGTON UNIVERSITY   (United States)

^t Hospital of Prato   (Italy)

more..

Author keywords

Breast cancer; Intrinsic subtypes; Receptor expression

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; ERBB2 PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR TYPING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CLASSIFICATION; BIOSYNTHESIS; CANCER STAGING; CLASSIFICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; TRIPLE NEGATIVE BREAST CANCER;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84929078023     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0372     Document Type: Article

References (35)

1. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010; 134:e48-e72.
2. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations forhuman epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
3. Wolff AC, Hammond ME, Hayes DF. Re: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 2012;104: 957-958.
4. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
5. Loi S, Haibe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-1246.
6. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004;351: 2817-2826.
7. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptorpositive breast cancer. Clin Cancer Res 2010;16: 5222-5232.
8. Dowsett M, Sestak I, Lopez-Knowles E et al. Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013;31:2783-2790.
9. Dubsky P, Filipits M, Jakesz R et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 2013;24: 640-647.
10. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-2767.
11. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 2012;486:395-399.
12. Prat A, Adamo B, Cheang MC et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. The Oncologist 2013; 18:123-133.
13. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
14. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
15. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167.
16. Martín M, Rodríguez-Lescure A, Ruiz A et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100:805-814.
17. Levine MN, Pritchard KI, Bramwell VH et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:5166-5170.
18. Bramwell VH, Pritchard KI, Tu D et al. A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal womenwith early breast cancer (National Cancer Institute of Canada—Clinical TrialsGroup Trial,MA.12). Ann Oncol 2010;21:283-290.
19. Cheang MC, Voduc KD, Tu D et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 2012;18:2402-2412.
20. Chia SK, Bramwell VH, Tu D et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012;18:4465-4472.
21. Martín M, Prat A, Rodríguez-Lescure A et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. BreastCancer Res Treat 2013;138:457-466.
22. Benjamini Y, Hochberg H. Controlling the false discovery rate:Apractical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289-300.
23. Iwamoto T, Booser D, Valero V et al. Estrogen receptor (ER)mRNAand ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012;30:729-734.
24. Prat A, Parker JS, Fan C et al. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat 2012;135:301-306.
25. Prat A, Parker JS, KarginovaO et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
26. Lehmann-Che J, Hamy AS, Porcher R et al. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 2013;15:R37.
27. Carey LA, Berry DA, Ollila DW et al. Clinical and translational results of CALGB 40601: Aneoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J Clin Oncol 2013;31 (suppl):500a.
28. Prat A, Bianchini G, ThomasMet al. Researchbased PAM50 subtype predictor identifies higher responsesand improved survival outcomesinHER2-positive breast cancer in the NOAH study. Clin Cancer Res 2014;20:511-521.
29. Prat A, Carey LA, Adamo B et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst 2014;106:dju 152.
30. Carey LA, Barrry WT, Pitcher BN et al. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). J Clin Oncol 2014;32(suppl):506a.
31. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.
32. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-1804.
33. Ali AM, Provenzano E, Bartlett JM et al. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. Int J Cancer 2013;133:1470-1478.
34. Chapman JA, Nielsen TO, Ellis MJ et al. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on diseasefree survival in NCIC CTG MA.12 Trial and BC Cohort. Breast Cancer Res 2013;15:R71.
35. Prat A, Cheang MC, Martín M et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013;31: 203-209.